Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations

K Baksh, J Weber - Seminars in oncology, 2015 - Elsevier
Over the last two decades, our understanding of the molecular basis of immunity has
revealed the complexity of regulatory pathways involved in immune responses to cancer. A
significant body of data support the critical importance of immune checkpoints in the control
of the adaptive immune response to malignancy, and suggest that inhibitors of those
checkpoints might have significant utility in treating cancer. This has been borne out by the
recent US Food and Drug Administration (FDA) approvals of two different antibodies, one …